Neoadjuvant gemcitabine and nab‐paclitaxel for borderline resectable pancreatic cancers: Intention‐to‐treat analysis compared with upfront surgery

We evaluated efficacy of neoadjuvant therapy with gemcitabine and nab‐paclitaxel (GNP‐NAT) in borderline resectable pancreatic cancer (BR‐PC) patients compared to conventional upfront surgery (UPS).

[1]  Y. Nagakawa,et al.  Precise anatomical resection based on structures of nerve and fibrous tissue around the superior mesenteric artery for mesopancreas dissection in pancreaticoduodenectomy for pancreatic cancer , 2020, Journal of hepato-biliary-pancreatic sciences.

[2]  A. Saiura,et al.  Radiologically occult metastatic pancreatic cancer: how can we avoid unbeneficial resection? , 2019, Langenbeck's Archives of Surgery.

[3]  Patrick B. Schwartz,et al.  Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer. , 2019, Annals of surgery.

[4]  W. Harmsen,et al.  Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer. , 2019, Annals of surgery.

[5]  N. Orsini,et al.  Surgery Improves Survival After Neoadjuvant Therapy for Borderline and Locally Advanced Pancreatic Cancer , 2019, Annals of surgery.

[6]  T. Fujii,et al.  Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP-05). , 2019, Journal of Clinical Oncology.

[7]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[8]  Thierry Lecomte,et al.  FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer , 2018, The New England journal of medicine.

[9]  T. Ishizawa,et al.  Optimal Extent of Superior Mesenteric Artery Dissection during Pancreaticoduodenectomy for Pancreatic Cancer: Balancing Surgical and Oncological Safety , 2018, Journal of Gastrointestinal Surgery.

[10]  P. Bachellier,et al.  Pancreatectomy With Arterial Resection for Pancreatic Adenocarcinoma: How Can It Be Done Safely and With Which Outcomes?: A Single Institution's Experience With 118 Patients. , 2018, Annals of surgery.

[11]  S. Choi,et al.  Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial , 2018, Annals of surgery.

[12]  Jeffrey W. Clark,et al.  Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial , 2018, JAMA oncology.

[13]  H. Zeh,et al.  FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma , 2018, Annals of Surgical Oncology.

[14]  G. Tienhoven,et al.  Meta‐analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer , 2018, The British journal of surgery.

[15]  N. Sata,et al.  A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer , 2018, Cancer Chemotherapy and Pharmacology.

[16]  M. McCarter,et al.  Perioperative and Survival Outcomes Following Neoadjuvant FOLFIRINOX versus Gemcitabine Abraxane in Patients with Pancreatic Adenocarcinoma. , 2018, JOP : Journal of the pancreas.

[17]  M. Büchler,et al.  The TRIANGLE operation - radical surgery after neoadjuvant treatment for advanced pancreatic cancer: a single arm observational study. , 2017, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[18]  S. Yamada,et al.  Effect of Neoadjuvant Nab-Paclitaxel plus Gemcitabine Therapy on Overall Survival in Patients with Borderline Resectable Pancreatic Cancer: A Prospective Multicenter Phase II Trial (NAC-GA Trial) , 2017, Oncology.

[19]  M. Baltatzis,et al.  Superior mesenteric artery (SMA) resection during pancreatectomy for malignant disease of the pancreas: a systematic review. , 2017, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[20]  D. Gouma,et al.  The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After , 2017, Surgery.

[21]  T. Ishizawa,et al.  Distal Pancreatectomy with Celiac Axis Resection Combined with Reconstruction of the Left Gastric Artery , 2017, Journal of Gastrointestinal Surgery.

[22]  C. Sperti,et al.  Pancreatic resection in very elderly patients: A critical analysis of existing evidence , 2017, World journal of gastrointestinal oncology.

[23]  N. Sata,et al.  Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01) , 2016, The Lancet.

[24]  A. Saiura,et al.  Pancreatoduodenectomy With Systematic Mesopancreas Dissection Using a Supracolic Anterior Artery-first Approach , 2015, Annals of surgery.

[25]  J. Kench,et al.  Meta‐analysis of radical resection rates and margin assessment in pancreatic cancer , 2015, The British journal of surgery.

[26]  D. Santini,et al.  Neoadjuvant Chemoradiotherapy and Surgery Versus Surgery Alone in Resectable Pancreatic Cancer: A Single-Center Prospective, Randomized, Controlled Trial Which Failed to Achieve Accrual Targets , 2015, Journal of Gastrointestinal Surgery.

[27]  Jeffrey W. Clark,et al.  "Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer." , 2017, Annals of surgery.

[28]  J. Furuse,et al.  Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer , 2014, Cancer science.

[29]  W. Hohenberger,et al.  Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer , 2014, Strahlentherapie und Onkologie.

[30]  H. Zeh,et al.  Serum CA 19-9 Response to Neoadjuvant Therapy is Associated with Outcome in Pancreatic Adenocarcinoma , 2014, Annals of Surgical Oncology.

[31]  D. Gouma,et al.  Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). , 2014, Surgery.

[32]  E. Nakakura,et al.  Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

[33]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[34]  E. Nakakura,et al.  Pancreatic Adenocarcinoma, Version 1.2019. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[35]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[36]  H. Toyokawa,et al.  Selective Use of Staging Laparoscopy Based on Carbohydrate Antigen 19-9 Level and Tumor Size in Patients With Radiographically Defined Potentially or Borderline Resectable Pancreatic Cancer , 2011, Pancreas.

[37]  M. Makuuchi,et al.  The Clavien-Dindo Classification of Surgical Complications: Five-Year Experience , 2009, Annals of surgery.

[38]  Jeffrey E. Lee,et al.  Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. , 2008, Journal of the American College of Surgeons.

[39]  D. Gouma,et al.  Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). , 2007, Surgery.

[40]  M. Choti,et al.  Impact of Total Lymph Node Count and Lymph Node Ratio on Staging and Survival after Pancreatectomy for Pancreatic Adenocarcinoma: A Large, Population-Based Analysis , 2007, Annals of Surgical Oncology.

[41]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[42]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[43]  F. Ames,et al.  Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. , 1992, Archives of surgery.

[44]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.